Literature DB >> 187771

Feline leukemia virus infection: age-related variation in response of cats to experimental infection.

E A Hoover, R G Olsen, W D Hardy, J P Schaller, L E Mathes.   

Abstract

Sixty-seven specific-pathogen-free cats of various ages (newborn, 2 wk, 1 mo, 2 mo, 4 mo, and 1 yr) were inoculated ip with either the Rickard (R) or the Kawakami-Theilen (KT) strain of feline leukemia virus (FeLV). Susceptibility to FeLV was judged by induction of a) FeLV group-specific antigens (gsa) in leukocytes, b) FeLV-related disease, c) antibody to feline oncornavirus-associated cell membrane antigen (FOCMA), and d) virus-neutralizing (VN) antibody. Susceptibility to FeLV-decreased with age. Persistent viremia and FeLV-related disease developed in 100% of cats inoculated as newborns, in 85% of cats inoculated at 2 weeks to 2 months of age, and in 15% of cats inoculated at 4 months or 1 year of age. Cats susceptible to FeLV leukemogenesis became persistently FeLV gsa-positive (viremic) at 4 weeks post inoculation and thereafter and produced little or no FOCMA or VN antibody. Cats that resisted leukemogenesis by FeLV all developed persistent FOCMA and VN titers and never became FeLV gsa-positive. The disease in inoculated cats was influenced by virus strain; FeLV-R induced predominantly thymic lymphosarcoma, whereas FeLV-KT caused fatal nonregenerative anemia without concurrent neoplasia.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 187771     DOI: 10.1093/jnci/57.2.365

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  27 in total

1.  Effects of cobra venom factor treatment on latent feline leukemia virus infection.

Authors:  E H Kraut; J L Rojko; R G Olsen; D L Tuomari
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

2.  Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy.

Authors:  L E Mathes; K A Hayes; G Kociba
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 3.  Immunopathology induced by the feline leukemia virus.

Authors:  W D Hardy
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

Authors:  L Hanlon; D Argyle; D Bain; L Nicolson; S Dunham; M C Golder; M McDonald; C McGillivray; O Jarrett; J C Neil; D E Onions
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes.

Authors:  J N Flynn; L Hanlon; O Jarrett
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

6.  Feline leukemia virus immunity induced by whole inactivated virus vaccination.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2009-10-31       Impact factor: 2.046

7.  Passive immunity to feline leukemia: evaluation of immunity from dams naturally infected and experimentally vaccinated.

Authors:  E A Hoover; J P Schaller; L E Mathes; R G Olsen
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

8.  McDonough feline sarcoma virus: characterization of the molecularly cloned provirus and its feline oncogene (v-fms).

Authors:  L Donner; L A Fedele; C F Garon; S J Anderson; C J Sherr
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

9.  Epizootiology and management of feline leukemia virus in the Florida puma.

Authors:  Mark W Cunningham; Meredith A Brown; David B Shindle; Scott P Terrell; Kathleen A Hayes; Bambi C Ferree; R T McBride; Emmett L Blankenship; Deborah Jansen; Scott B Citino; Melody E Roelke; Richard A Kiltie; Jennifer L Troyer; Stephen J O'Brien
Journal:  J Wildl Dis       Date:  2008-07       Impact factor: 1.535

10.  Feline leukemia virus subgroup C phenotype evolves through distinct alterations near the N terminus of the envelope surface glycoprotein.

Authors:  J Brojatsch; B S Kristal; G A Viglianti; R Khiroya; E A Hoover; J I Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.